KR19990014353A - 췌도의 대량 배양증식방법 - Google Patents
췌도의 대량 배양증식방법 Download PDFInfo
- Publication number
- KR19990014353A KR19990014353A KR1019980043491A KR19980043491A KR19990014353A KR 19990014353 A KR19990014353 A KR 19990014353A KR 1019980043491 A KR1019980043491 A KR 1019980043491A KR 19980043491 A KR19980043491 A KR 19980043491A KR 19990014353 A KR19990014353 A KR 19990014353A
- Authority
- KR
- South Korea
- Prior art keywords
- pancreatic islets
- added
- pancreatic
- islets
- pancreas
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004153 islets of langerhan Anatomy 0.000 title claims abstract description 85
- 230000035755 proliferation Effects 0.000 title description 8
- 210000000496 pancreas Anatomy 0.000 claims abstract description 37
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims abstract description 19
- 239000007952 growth promoter Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000002516 radical scavenger Substances 0.000 claims abstract description 14
- 108010035532 Collagen Proteins 0.000 claims abstract description 13
- 102000008186 Collagen Human genes 0.000 claims abstract description 13
- 229920001436 collagen Polymers 0.000 claims abstract description 13
- 238000010257 thawing Methods 0.000 claims abstract description 13
- 239000001963 growth medium Substances 0.000 claims abstract description 12
- 210000000601 blood cell Anatomy 0.000 claims abstract description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 10
- 230000012292 cell migration Effects 0.000 claims abstract description 8
- 238000009792 diffusion process Methods 0.000 claims abstract description 8
- 210000002966 serum Anatomy 0.000 claims abstract description 8
- 238000005138 cryopreservation Methods 0.000 claims abstract description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 5
- 229930006000 Sucrose Natural products 0.000 claims abstract description 5
- 239000013078 crystal Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims abstract description 5
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 5
- 239000005720 sucrose Substances 0.000 claims abstract description 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 44
- 102000004877 Insulin Human genes 0.000 claims description 22
- 108090001061 Insulin Proteins 0.000 claims description 22
- 229940125396 insulin Drugs 0.000 claims description 22
- 210000004027 cell Anatomy 0.000 claims description 9
- 238000012258 culturing Methods 0.000 claims description 7
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical group NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 6
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 6
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 6
- 244000309466 calf Species 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 238000011534 incubation Methods 0.000 claims description 6
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 4
- 102000015336 Nerve Growth Factor Human genes 0.000 claims description 4
- 229940053128 nerve growth factor Drugs 0.000 claims description 4
- 108090000190 Thrombin Proteins 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 230000002440 hepatic effect Effects 0.000 claims description 3
- 108010082117 matrigel Proteins 0.000 claims description 3
- 229960003966 nicotinamide Drugs 0.000 claims description 3
- 235000005152 nicotinamide Nutrition 0.000 claims description 3
- 239000011570 nicotinamide Substances 0.000 claims description 3
- 229960004072 thrombin Drugs 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 claims description 2
- 229940082569 selenite Drugs 0.000 claims description 2
- MCAHWIHFGHIESP-UHFFFAOYSA-L selenite(2-) Chemical compound [O-][Se]([O-])=O MCAHWIHFGHIESP-UHFFFAOYSA-L 0.000 claims description 2
- 210000004292 cytoskeleton Anatomy 0.000 claims 1
- 239000000499 gel Substances 0.000 claims 1
- 238000009630 liquid culture Methods 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 22
- 206010012601 diabetes mellitus Diseases 0.000 abstract description 15
- 230000000694 effects Effects 0.000 abstract description 8
- 230000007774 longterm Effects 0.000 abstract description 2
- 235000012054 meals Nutrition 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 17
- 210000004369 blood Anatomy 0.000 description 16
- 239000008280 blood Substances 0.000 description 16
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 10
- 239000008103 glucose Substances 0.000 description 10
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 229960003957 dexamethasone Drugs 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 102000051325 Glucagon Human genes 0.000 description 4
- 108060003199 Glucagon Proteins 0.000 description 4
- 229960004666 glucagon Drugs 0.000 description 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 4
- 210000000130 stem cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 230000002218 hypoglycaemic effect Effects 0.000 description 3
- 230000003914 insulin secretion Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- 102000013275 Somatomedins Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000000417 fungicide Substances 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000002989 hepatic vein Anatomy 0.000 description 1
- -1 hydrocorisone Chemical compound 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000003240 portal vein Anatomy 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0676—Pancreatic cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/16—Physical preservation processes
- A01N1/162—Temperature processes, e.g. following predefined temperature changes over time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/105—Insulin-like growth factors [IGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/12—Hepatocyte growth factor [HGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/135—Platelet-derived growth factor [PDGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/39—Steroid hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/585—Integrins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Obesity (AREA)
- Pharmacology & Pharmacy (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dentistry (AREA)
- Environmental Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019980043491A KR19990014353A (ko) | 1998-10-17 | 1998-10-17 | 췌도의 대량 배양증식방법 |
| CA002286530A CA2286530A1 (en) | 1998-10-17 | 1999-10-15 | Method for culturing langerhans islets and islet autotransplantation islet regeneration |
| KR1019990044934A KR100354931B1 (ko) | 1998-10-17 | 1999-10-16 | 췌도의 대량 배양증식 및 증식한 췌도에 의한 당뇨치료방법 |
| EP99308203A EP0994185B1 (en) | 1998-10-17 | 1999-10-18 | Method for culturing Langerhans islets cells |
| JP11295808A JP2000139455A (ja) | 1998-10-17 | 1999-10-18 | ランゲルハンス島の培養及び島自己移植島再生方法 |
| DE69922610T DE69922610T2 (de) | 1998-10-17 | 1999-10-18 | Verfahren zur Kultivierung von Langerhansinsel-Zellen |
| AU55930/99A AU775691B2 (en) | 1998-10-17 | 1999-10-18 | Method for culturing langerhans islets and islet autotransplantation islet regeneration |
| EP03013538A EP1344818A1 (en) | 1998-10-17 | 1999-10-18 | Method for culturing Langerhans islets cells |
| AT99308203T ATE284952T1 (de) | 1998-10-17 | 1999-10-18 | Verfahren zur kultivierung von langerhansinsel- zellen |
| US10/191,885 US20020187551A1 (en) | 1998-10-17 | 2002-07-08 | Method for culturing langerhans islets and islet autotransplantation islet regeneration |
| US10/199,710 US20030008394A1 (en) | 1998-10-17 | 2002-07-19 | Method for culturing langerhans islets and islet autotransplantation islet regeneration |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019980043491A KR19990014353A (ko) | 1998-10-17 | 1998-10-17 | 췌도의 대량 배양증식방법 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR19990014353A true KR19990014353A (ko) | 1999-02-25 |
Family
ID=19554380
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019980043491A Pending KR19990014353A (ko) | 1998-10-17 | 1998-10-17 | 췌도의 대량 배양증식방법 |
Country Status (7)
| Country | Link |
|---|---|
| EP (2) | EP1344818A1 (enExample) |
| JP (1) | JP2000139455A (enExample) |
| KR (1) | KR19990014353A (enExample) |
| AT (1) | ATE284952T1 (enExample) |
| AU (1) | AU775691B2 (enExample) |
| CA (1) | CA2286530A1 (enExample) |
| DE (1) | DE69922610T2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100855104B1 (ko) * | 2006-06-28 | 2008-08-29 | 피더블유제네틱스코리아 주식회사 | 췌도세포의 장기 보존을 위한 취급방법 |
| WO2011010796A3 (ko) * | 2009-07-22 | 2011-03-24 | (주)시지바이오 | 이식용 동종 피부의 처리 방법 및 그로부터 제조된 동결보존동종피부 |
| KR101327630B1 (ko) * | 2012-03-05 | 2013-11-13 | 울산대학교 산학협력단 | 아텔로콜라겐을 이용한 췌도세포 이식용 담체의 제조방법 그리고 이를 이용하여 제조된 인공췌장 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6592618B2 (en) * | 2000-02-29 | 2003-07-15 | The Brigham And Women's Hospital, Inc. | In vitro modification of cardiac valvular xenografts |
| DE10134667A1 (de) * | 2001-07-20 | 2003-02-06 | Neuroprogen Gmbh Leipzig | Verfahren zur Herstellung isolierter Zellkulturen, Kulturmedium zur Kultivierung von Zellkulturen und Zellkultur |
| SI1636348T1 (sl) * | 2003-06-20 | 2010-01-29 | Vrije Universiteit Brussel Vub | Postopek za pridobivanje beta celic iz eksokrinskih celic trebuĺ ne slinavke |
| WO2005054450A1 (en) * | 2003-12-01 | 2005-06-16 | Vertex Pharmaceuticals Incorporated | Compositions comprising fetal liver cells and methods useful for hcv infection |
| EP1737944A4 (en) * | 2004-03-09 | 2010-03-24 | Lifescan Inc | METHOD FOR GENERATING INSULIN-PRODUCING CELLS |
| US20090060843A1 (en) * | 2007-08-31 | 2009-03-05 | Biocrine Ab | Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes |
| EP2546334A4 (en) * | 2010-03-12 | 2014-10-29 | Fundación Progreso Y Salud | METHOD FOR THE IN VITRO PROLIFERATION OF TISSUE DERIVED FROM TISSUE ENDORMALLY ORIGINATED CELLS |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE456164B (sv) * | 1980-08-20 | 1988-09-12 | Kjell Nilsson | Forfarande for immobilisering, odling och efterfoljande frigoring av animala celler samt mikroberare av gelatin med absorberade animala celler |
| EP0363125A3 (en) * | 1988-10-03 | 1990-08-16 | Hana Biologics Inc. | Proliferated pancreatic endocrine cell product and process |
| US5116753A (en) * | 1991-07-30 | 1992-05-26 | The Salk Institute For Biological Studies | Maintenance of pancreatic islets |
| US5587309A (en) * | 1994-04-29 | 1996-12-24 | The United States Of America As Represented By The Department Of Health And Human Services | Method of stimulating proliferation and differentiation of human fetal pancreatic cells ex vivo |
| AU7443996A (en) * | 1995-10-30 | 1997-05-22 | Vivorx, Inc. | Method for ex vivo proliferation and differentiation of adult pancreatic islet cells, media useful therefor and uses thereof |
-
1998
- 1998-10-17 KR KR1019980043491A patent/KR19990014353A/ko active Pending
-
1999
- 1999-10-15 CA CA002286530A patent/CA2286530A1/en not_active Abandoned
- 1999-10-18 DE DE69922610T patent/DE69922610T2/de not_active Expired - Fee Related
- 1999-10-18 EP EP03013538A patent/EP1344818A1/en not_active Withdrawn
- 1999-10-18 AT AT99308203T patent/ATE284952T1/de not_active IP Right Cessation
- 1999-10-18 EP EP99308203A patent/EP0994185B1/en not_active Expired - Lifetime
- 1999-10-18 AU AU55930/99A patent/AU775691B2/en not_active Ceased
- 1999-10-18 JP JP11295808A patent/JP2000139455A/ja active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100855104B1 (ko) * | 2006-06-28 | 2008-08-29 | 피더블유제네틱스코리아 주식회사 | 췌도세포의 장기 보존을 위한 취급방법 |
| WO2011010796A3 (ko) * | 2009-07-22 | 2011-03-24 | (주)시지바이오 | 이식용 동종 피부의 처리 방법 및 그로부터 제조된 동결보존동종피부 |
| US11013228B2 (en) | 2009-07-22 | 2021-05-25 | Cg Bio Co., Ltd. | Method of processing allograft skin for transplantation, and cryopreserved allograft skin produced thereby |
| KR101327630B1 (ko) * | 2012-03-05 | 2013-11-13 | 울산대학교 산학협력단 | 아텔로콜라겐을 이용한 췌도세포 이식용 담체의 제조방법 그리고 이를 이용하여 제조된 인공췌장 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE69922610D1 (de) | 2005-01-20 |
| AU5593099A (en) | 2000-04-20 |
| EP0994185A2 (en) | 2000-04-19 |
| ATE284952T1 (de) | 2005-01-15 |
| EP1344818A1 (en) | 2003-09-17 |
| CA2286530A1 (en) | 2000-04-17 |
| EP0994185B1 (en) | 2004-12-15 |
| JP2000139455A (ja) | 2000-05-23 |
| DE69922610T2 (de) | 2005-12-15 |
| AU775691B2 (en) | 2004-08-12 |
| EP0994185A3 (en) | 2001-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6506599B1 (en) | Method for culturing langerhans islets and islet autotransplantation islet regeneration | |
| Horaguchi et al. | Preparation of viable islet cells from dogs by a new method | |
| KR100374976B1 (ko) | 기능성랑게르한스섬의시험관내성장및그생체내사용방법 | |
| HU228887B1 (hu) | Keratinociták, melyek felhasználhatók biológiailag aktív anyagként sebek kezelésénél | |
| JPH09509827A (ja) | 機能性ヒト組織の再生と利用 | |
| KR19990014353A (ko) | 췌도의 대량 배양증식방법 | |
| Takahashi et al. | Engineering pancreatic tissues from stem cells towards therapy | |
| CN103429733B (zh) | 培养的胰岛 | |
| KR102148998B1 (ko) | 간세포 및 캡슐화한 간세포 구상체의 동결 보존을 위한 동결보존용 무혈청 용액 및 이를 이용한 동결보존법 | |
| CA2805717C (en) | Methods for increasing isolation yields of cellular products | |
| WO1986001530A1 (en) | A process for proliferation of wholly or partially differentiated beta-cellls | |
| Choi et al. | Scaling Insulin-Producing Cells by Multiple Strategies | |
| Charles et al. | Storage and microencapsulation of islets for transplantation | |
| KR20000029133A (ko) | 췌도의 대량 배양증식 및 증식한 췌도에 의한 당뇨치료방법 | |
| CN117343904B (zh) | 一种瘢痕疙瘩类器官培养基及培养方法 | |
| Kojima et al. | Culture of the islets of Langerhans for transplantation | |
| Woods et al. | Enhanced recovery of cryopreserved islets using SIS | |
| Sandler et al. | Tissue Culture and Cryopreservation of | |
| Otonkoski et al. | Nicotinamide and sodium butyratye for the induction of fetal porcine β-cell differentiation prior to transplantation | |
| Malinin et al. | Growth stimulation of human chondrocytes in primary monolayer cultures by triiothyronine | |
| Durowicz et al. | Mechanism of trapping of intravenously transplanted lymphocytes in the liver | |
| Caluse et al. | Splenic hepatocyte autotranplantation in pigs: New technical aspects | |
| Diakonov et al. | Long-term survival and production of testosterone by immobilized human embryonic testis fragments | |
| Gao et al. | Single donor transplantation of fresh and cryopreserved pancreatic fragments into the liver parenchyma in syngeneic rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 19981017 |
|
| G15R | Request for early publication | ||
| PG1501 | Laying open of application |
Comment text: Request for Early Opening Patent event code: PG15011R01I Patent event date: 19981106 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 19990903 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 19981017 Comment text: Patent Application |
|
| PC1204 | Withdrawal of earlier application forming a basis of a priority claim |
Patent event date: 19981017 Comment text: Patent Application Patent event code: PC12041R01I |